QSP SIG Leadership Team

Dr. Cesar Pichardo currently works in Systems Medicine at AstraZeneca (part of the Clinical Pharmacology and Safety Science Department) providing support with mechanistic modelling for drug development in oncology and other therapeutic areas. Cesar has worked as a Modelling and Simulation scientist in various companies and environments for more than 20 years, including FMCG (Unilever), big pharma (Pfizer), finance (Moody’s), pharma consultancy services (Xenologiq and Certara) and academia (University College London, University of Sheffield and INSA Lyon).

He is a Chemical Engineer graduated from Simon Bolivar University (Venezuela), holds a MSc. In Systems Engineering from the same university and a PhD in Applied Maths from Ecole Centrale de Lille (France). Cesar is passionate about knowledge sharing and collaborative innovation. He actively engages with colleagues worldwide, aiming to drive QSP advancements through exchange of ideas. He is also a member of the European Federation of Chemical Engineering's "Chemical Engineering as Applied to Medicine" section which reflects his commitment to bridging the gap between disciplines and inspiring future generations in this exciting intersection of engineering and healthcare. 

Dr. Meghan (McCabe) Pryor is a passionate professional who balances her love for quantitative modeling with her commitments to family, fitness, and continuous growth. She holds a Ph.D. in Chemical Engineering from the University of New Mexico, alongside a B.Ch.E. in Chemical Engineering and a B.S. in Quantitative Biology from the University of Delaware. After completing a post-doctoral fellowship at Johns Hopkins University, Meghan began her industry career at Rosa & Co as a QSP modeler, where she gained deep expertise in a wide range of modeling techniques and therapeutic areas under the mentorship of Christina Friedrich. She currently works at Johnson & Johnson Innovative Medicine (formerly Janssen), where she leads efforts to drive the discovery and early development of small molecules and PROTACs in the Translational PKPD group. Meghan collaborates across functions and engages with a broad range of stakeholders and leaders, using her expertise in QSP and PKPD modeling to build confidence, reduce uncertainty, define effective first-in-human dosing strategies, and design optimized studies. She is also deeply committed to supporting women in leadership and fostering the next generation of female leaders. Outside of her professional life, Meghan enjoys spending time with her family, reading, crocheting, and riding her Peloton. 

Cristhyne holds a PhD in Machine Learning and Bioinformatics from Université de Rennes 1 (France), where she developed innovative applications of recurrent neural networks for disease diagnosis and age estimation in infants. She began her QSP career when she joined Nova in Silico in 2021 as a QSP modeler. In this role she has worked on integrating machine learning with mechanistic modeling, contributing to the development of translational models in diverse therapeutic areas, such as immunology, oncology, and respiratory diseases. Now in the roles of Project Manager and Head of Scientific Support, she works closely with
interdisciplinary teams to support advancing quantitative systems pharmacology modeling, including its integration with data-driven approaches, for translational and clinical research at Nova In Silico.

Dr. Hanwen Wang is a senior scientist in Systems Medicine at AstraZeneca, supporting the oncology portfolio with a focus on T-cell engagers. He received his Ph.D. in Biomedical Engineering from Johns Hopkins University, where he worked with Prof. Aleksander Popel on QSP modeling in immuno-oncology and clinical trial simulations in triple-negative breast cancer and non-small cell lung cancer. His work highlights the value of QSP models and virtual patients/digital twins for efficacy prediction, dose optimization, and biomarker identification, supporting decisions across preclinical and clinical stages.

Dr. Anna Kondic currently works in the Clinical Pharmacology and Pharmacometrics groups at Bristol Myers Squibb where she is responsible for all the pharmacometrics support in oncology, hematology and cell-based therapies. Anna has worked as a quantitative scientist in various therapeutic areas and companies over the last 22 years and has extensive experience in both mechanistic and empirical model across the whole spectrum of R&D, as well as reimbursement. She holds a PhD in mathematics from Duke University and MBA from Stern School of Business at New York University. Anna is particularly passionate about the use of quantitative methods to make personalized medicine a reality, especially for cancer patients. 

Anna is a competitive master artistic swimmer, participating in both national and international meets. She is particularly proud of having been the captain for the Merck Rhode Island team for Swim Across America in 2018. The charity swim that year raised more than 700 000 for cancer research at the Women and Infants Hospital in Providence, RI.